KRAS and pachyonychia congenita: Thus, single-cell RNA sequencing of CTCs promoted targeting of survivin inhibition by YM155 that is found to be beneficial for metastatic stage therapy in PC patients alone or in combination with chemo drugs, while the ctDNA was relevant as a biomarker for determining KRAS mutations and gemcitabine adjuvant chemotherapy in resected PC patients [29].